Prime.io joins 2BScientific as a supplier, expanding access to genome editing solutions across the UK and EU
Aug 4th 2026
-
Prime.io joins the 2BScientific supplier portfolio, making its genome editing tools, reagents and services available to researchers across the UK and Europe through a single trusted source
London, UK — Prime.io, a gene editing contract research organization (CRO) using AI-designed genome editing technology and automation to accelerate drug discovery, today announced that it has joined 2BScientific Limited as a supplier.
About 2BScientific
2BScientific Limited is a UK-based distributor of innovative life science products, serving customers across the UK, Europe and worldwide. Headquartered in Oxfordshire with an office in Munich, the ISO 9001 and ISO 14001 certified company supplies reagents, assays and custom services to researchers in academia, biotechnology, pharmaceutical companies and hospitals, alongside a long-standing commitment to environmental sustainability.
About Prime.io
Prime.io provides a comprehensive range of genome editing tools, reagents and services, with particular expertise in precise gene knock-in (KI) and targeted genome engineering. Its portfolio spans bespoke knock-in and knock-out cell line generation, custom sgRNAs, ssDNA and dsDNA donor templates, genome editing nucleases, pooled screening libraries, knock-out cell lines and lysates for antibody validation, and genome editing design services.
What the partnership brings
Through this partnership, 2BScientific customers gain access to both specialist genome editing expertise and the reagents required to support their research from a single trusted source. For researchers, this means a broader selection of high-quality genome engineering solutions, more streamlined experimental workflows, and reduced procurement complexity.
For Prime.io, joining an established distribution network extends the reach of its genome editing technologies to a wider research community across the UK and Europe, supported by 2BScientific's technical and customer service teams.
Dr Rex Li, Founder and Chief Executive Officer, Prime.io , said—
“On behalf of Prime.io Ltd, I am delighted to announce that Prime.io is joining 2BScientific Limited as a supplier, bringing our innovative genome editing solutions to researchers across the UK and Europe.
At Prime.io, we are committed to making advanced genome editing technologies more accessible, with particular expertise in precise gene knock-in (KI) and targeted genome engineering. Our goal is to empower researchers with reliable, high-quality solutions that accelerate scientific discovery with confidence.
As part of 2BScientific's trusted supplier portfolio, customers will gain access to our comprehensive range of products and services, including gene knock-in (KI) design and engineering services, gene editing reagents, gene knockout cell lines and lysates for antibody validation, and customized pooled screening solutions. Together, we are committed to delivering high-quality products, expert scientific support, and flexible, tailored services that simplify complex research workflows and help scientists achieve meaningful breakthroughs more efficiently.
I look forward to supporting the 2BScientific community and helping researchers advance life science discovery through innovation, collaboration and scientific excellence.”
Dr Farjad Ahmed, Chief Scientific Officer, 2BScientific Limited, said—
“We are delighted to welcome Prime.io Ltd as a new supplier to the 2BScientific portfolio. Prime.io provides a comprehensive range of genome editing tools, reagents and services, including bespoke knock-in and knockout cell line generation, custom sgRNAs, ssDNA and dsDNA donor templates, genome editing nucleases, pooled screening libraries and genome editing design services.
By adding Prime.io to our supplier network, we are expanding our ability to provide researchers with a broader selection of high-quality genome engineering solutions through a single trusted source. This partnership enables our academic, biotechnology and pharmaceutical customers to access both specialist genome editing expertise and the reagents required to support their research, helping to streamline experimental workflows, reduce procurement complexity and accelerate scientific discovery.
We look forward to working with Prime.io to support the growing needs of the genome editing research community.”
About Prime.io
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.
Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.
The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.
Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based in 167-169 Great Portland Street, 5th floor, London W1W 5PF.
To learn how we can accelerate your drug discovery research, please contact us:
Website: www.primeio.co.uk
LinkedIn: https://www.linkedin.com/company/108341309
Email: rex@primeio.co.uk